Bloomington’s 2025 economic story is about adapting and rising to meet challenges. Flexibility, strategic investment and ...

It is connected to a larger transaction in which Novo Nordisk’s controlling shareholder Novo Holdings will buy Catalent for $16.5 billion, or $63.50 per share, and merge it with a Novo Holdings ...

In accordance with the trilateral agreement, after approval by the FTC, Novo Nordisk will buy three Catalent plants from Novo Holdings for $11.7 billion. In particular, the deal includes plants in ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

View the latest Novo Nordisk A/S (NOVO.B) stock price, news, historical charts, analyst ratings and financial information from WSJ.